Description: Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
Home Page: www.huamedicine.com
Building A
Beijing,
China
Phone:
86 21 3810 1800
Officers
| Name | Title |
|---|---|
| Dr. Li Chen Ph.D. | Founder, CEO, Chief Scientific Officer & Exec. Director |
| Mr. Chien Cheng Lin | Exec. VP, CFO & Exec. Director |
| Dr. Di Hong | VP of Operation Department |
| Emily Yeh | Director of Corp. Fin. |
| Dr. Fuxing Tang | CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA |
| Ms. Wenjie Xu M.B.A. | VP and Head of Commercial Strategy & Marketing |
| Dr. Yi Zhang M.D., Ph.D. | Sr. VP of Pharma Devel. & Chief Medical Officer ? China |
| Dr. Jin She Ph.D. | Sr. VP of Chemical Manufacturing Control Department & Chief Manufacturing Officer |
| Dr. Yilei Fu M.B.A. | Sr. VP of Quality Assurance & Chief Quality Officer |
| Ms. Wing Yan Yuen FCIS, FCS | Company Sec. |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.4231 |
| Price-to-Sales TTM: | 160.9567 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 147 |